// App-Quantinova.ai

5037 : Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P).

Researchers

Presenter

  • Fred Saad

Principal Investigators

  • Karim Fizazi

  • Matthew R. Smith

  • Thomas W. Griffin

  • Anil Londhe

  • Dana E. Rathkopf

  • Arturo Molina

  • Charles J. Ryan

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Janssen Research & Development, Los Angeles, CA

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • University of Montreal, Montreal, QC, Canada

Locations

  • United States

  • Canada

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

  • Opiate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00887198

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved